

ASTRAZENECA PLC

Interim Financial Statements

31 March 2008



Registered number 2723534

PROFIT AND LOSS ACCOUNT
for the period/year ended

	Notes	31 March 2008 \$m	31 December 2007 \$m
Turnover		-	-
Operating costs		(3)	(11)
Operating loss		(3)	(11)
Income from shares in subsidiary undertakings	2	-	9,411
Other income		-	1
Profit on ordinary activities before interest		(3)	9,401
Net interest	3	13	17
Profit on ordinary activities before taxation		10	9,418
Taxation		-	(11)
Net profit for the period/year		10	9,407

STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES

For the period/year ended	31 March 2008 \$m	31 December 2007 \$m
Net profit for the period/year	10	9,407
Cash flow hedge in anticipation of debt issue	-	(21)
Total recognised gains for the period/year	10	9,386

BALANCE SHEET

	Notes	31 March 2008 \$m	Restated 31 December 2007 \$m
Fixed assets			
Fixed asset investments	5	30,386	31,128
Current assets			
External debtors - other		1	1
Debtors – amounts owed by subsidiaries	6	5,542	6,984
		5,543	6,985
Total assets		35,929	38,113
Creditors due within one year			
Short-term borrowings	7	(3,756)	(4,123)
Other creditors		(147)	(206)
Amounts owed to subsidiaries		(13)	(24)
		(3,916)	(4,353)
Net current assets		1,627	2,632
Total assets less current liabilities		32,013	33,760
Creditors due after more than one year			
Loans	8	(10,925)	(10,765)
Net assets		21,088	22,995
Capital and reserves			
Called-up share capital	9	364	364
Share premium account	10	1,889	1,888
Capital redemption reserve	10	91	91
Share-based payment	10	822	773
Other reserves	10	1,841	1,841
Profit and loss account	10	16,081	18,038
Shareholders' funds - equity interests	11	21,088	22,995

The interim financial statements on pages 1 to 7 were approved by the Board of Directors on 23 April 2008 and were signed on its behalf by



David R Brennan
Director



Simon Lowth
Director

NOTES RELATING TO THE FINANCIAL STATEMENTS

1 Basis of presentation of financial information

These AstraZeneca PLC non-statutory financial statements are presented in accordance with the accounting policies set out in the AstraZeneca Annual Report and Form 20-F Information 2007

During the period, the Company has adopted the provisions of UITF 44 'Group and Treasury Share Transactions'. The effect of adoption has been to increase the investments in subsidiaries and to recognise a share-based payments reserve. For the year ended 31 December 2007 this has had the effect of increasing shareholders' funds and investments by \$773m

These financial statements do not constitute statutory accounts of the Company within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2007 have been filed with the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985

2 Income from shares in subsidiary undertakings

	31 March 2008 \$m	31 December 2007 \$m
Dividends received from subsidiary undertakings	-	9,411

3 Net interest

	31 March 2008 \$m	31 December 2007 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(5)	(20)
External interest payable	(198)	(489)
Net exchange and hedge losses	-	(8)
	(203)	(517)
Interest receivable and similar income		
Receivable from subsidiary undertakings	203	534
Net exchange and hedge gains	13	-
	216	534
Net interest	13	17

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

4 Dividends to shareholders

	31 March 2008 per share	31 Dec 2007 per share	31 March 2008 \$m	31 Dec 2007 \$m
2 nd interim/final	\$1 35	\$1 23	1,967	1,885
1 st interim	-	\$0 52	-	773
	\$1 35	\$1 75	1,967	2,658

5 Fixed asset investments

	Shares \$m	Loans \$m	Total \$m
Cost			
At beginning of year	15,286	15,069	30,355
Prior year adjustment on adoption of UITF 44	773	-	773
Restated at beginning of year	16,059	15,069	31,128
Additions	14,749	-	14,749
Disposals	(14,700)	-	(14,700)
Exchange (Euro and GBP bonds)	-	159	159
Amortisation	-	2	2
Repayment of loan	-	(952)	(952)
At end of period	16,108	14,278	30,386

On 11 March 2008, the Company sold its wholly owned subsidiary, AstraZeneca UK Limited, to its wholly owned subsidiary, AstraZeneca Intermediate Holdings Limited, in consideration for the issue of further shares in AstraZeneca Intermediate Holdings Limited. There has been no overall net change in ownership of AstraZeneca UK Limited and consequently the Company will hold the investment at its pre-transfer carrying amount of \$14,700m.

6 Debtors – amounts owed by subsidiaries

	31 March 2008 \$m	31 December 2007 \$m
AstraZeneca Treasury Limited	5,431	6,873
AstraZeneca UK Limited	111	111
	5,542	6,984

The balance owed by AstraZeneca Treasury Limited at 31 March 2008 includes \$3,761m (31 December 2007 \$4,138m) on-lent proceeds from commercial paper issues.

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

7 Short-term borrowings

	31 March 2008 \$m	31 December 2007 \$m
Unclaimed dividends	19	11
External debt – commercial paper issues	3,737	4,112
	3,756	4,123

8 Creditors due after more than one year

	Repayment dates	31 March 2008 \$m	31 December 2007 \$m
Loans – owed to subsidiaries (unsecured)			
US dollars			
7 2% loan	2023	283	283
Loans – external (unsecured)			
US dollars			
Floating rate note	2009	649	649
5 4% bond	2012	1,741	1,741
5 4% bond	2014	747	747
5 9% bond	2017	1,741	1,741
6 45% bond	2037	2,715	2,715
Euros			
4 625% bond	2010	1,181	1,099
5 125% bond	2015	1,180	1,099
Pounds sterling			
5 75% bond	2031	688	691
		10,925	10,765

With the exception of the floating rate note, all loans are at fixed interest rates

9 Called-up share capital

	Authorised	Allotted, called-up and fully paid	
	31 March 2008 \$m	31 March 2008 \$m	31 Dec 2007 \$m
Ordinary Shares (\$0 25 each)	364	364	364
Unissued Ordinary Shares (\$0 25 each)	236	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	364	364

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

9 Called-up share capital (continued)

The movements in share capital during the period can be summarised as follows

	No. shares (millions)	\$m
At 1 January 2008	1,457	364
Issues of shares	-	-
Re-purchase of shares	-	-
At 31 March 2008	1,457	364

10 Reserves

	Share premium account \$m	Capital redemption reserve \$m	Share- based payment \$m	Other reserves \$m	Profit and loss account \$m	Total 31 Mar 2008 \$m	Total 31 Dec 2007 \$m
At beginning of year	1,888	91	-	1,841	18,038	21,858	19,063
Prior year adjustment - UITF 44	-	-	773	-	-	773	624
Restated opening reserves	1,888	91	773	1,841	18,038	22,631	19,687
Profit for the period/year	-	-	-	-	10	10	9,407
Dividends	-	-	-	-	(1,967)	(1,967)	(2,658)
Cash flow hedge in anticipation of debt issue	-	-	-	-	-	-	(21)
Share-based payment	-	-	49	-	-	49	149
Share re-purchases	-	-	-	-	-	-	(4,150)
Share premiums	1	-	-	-	-	1	217
At end of period	1,889	91	822	1,841	16,081	20,724	22,631
Distributable reserves at end of period	-	-	-	1,841	12,973	14,814	15,819

At 31 March 2008, \$3,108m (31 December 2007 \$4,060m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During the period \$952m of the profit was released by repayment. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

During the period, the Company adopted the provisions of UITF 44 'Group and Treasury Share Transactions' with the effect of introducing a share based payment reserve as a prior year adjustment.

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

11 Reconciliation of movements in shareholders' funds

	31 March 2008 \$m	31 December 2007 \$m
Opening shareholders' funds as previously stated	22,222	19,446
Prior year adjustment on adoption of UITF 44	773	624
Restated opening shareholders' funds	22,995	20,070
Profit for the period/year	10	9,407
Dividends	(1,967)	(2,658)
Cash flow hedge in respect of anticipated debt issue	-	(21)
	(1,957)	6,728
Issues of AstraZeneca PLC Ordinary Shares	1	218
Re-purchase of AstraZeneca PLC Ordinary Shares	-	(4,170)
Share-based payment	49	149
Net increase/(reduction) in shareholders' funds	(1,907)	2,925
Shareholders' funds at end of period/year	21,088	22,995

12 Commitments and contingent liabilities

Exanta (ximelagatran)

Four putative and essentially similar securities class actions were filed in the US against AstraZeneca PLC, Håkan Mogren (who currently serves as a Director of AstraZeneca PLC), Sir Tom McKillop, Jonathan Symonds and Percy Barnevik (who are former Directors of AstraZeneca PLC) between January and March 2005. The defendants deny the allegations made in the lawsuit and will vigorously defend the action. The defendants filed a motion in 2006 to dismiss the action, and the court heard oral argument on defendants' motion on 15 April 2008.